Seelos Therapeutics Inc (NASDAQ:SEEL) finished Friday with a subtraction of $0.0 to close at $0.18, an upside of 3.78 percent. An average of 14,480,300 shares of common stock have been traded in the last five days. There was a gain of $0.0211 in the past week, and it reached a new high 10 times over the past 12 months. The last 20 days have seen an average of 9,889,015 shares traded, while the 50-day average volume stands at 4,528,210.
SEEL stock has decreased by -82.96% in the last month. The company shares reached their 1-month lowest point of $0.1500 on 09/25/23. With the stock rallying to its 52-week high on 08/03/23, shares of the company touched a low of $0.15 and a high of $1.66 in 52 weeks. It has reached a new high 23 times so far this year and lost -72.90% or -$0.4950 in price. In spite of this, the price is down -88.92% from the 52-week high.
Valuation Metrics
Seelos Therapeutics Inc (SEEL) stock’s beta is 2.13. Other valuation ratios to consider include the trailing price-to-sales (P/S) ratio at 20.56.
Financial Health
The quick ratio of Seelos Therapeutics Inc for the three months ended June 29 was 0.21, and the current ratio was 0.21, indicating that the company is not able to meet its debt obligations. Its gross profit as reported stood at $70.92 million.
Earnings Surprise
In the quarter under review, the net income was down than the previous quarter. The company posted a net income of -$29.5 million in the quarter, while revenues of -$13.43 million were grew 27.9%. The analyst consensus anticipated Seelos Therapeutics Inc’s latest quarter earnings to come in at -$0.09 per share, but it turned out to be -$0.22, a -144.40% surprise. For the quarter, EBITDA amounted to -$10.94 million. Shareholders own equity worth $127.36 million.
Technical Picture
From a technical analysis perspective, let’s take a brief look at Seelos Therapeutics Inc (SEEL) price momentum. RSI 9-day as of the close on 29 September was 20.36%, suggesting the stock is oversold, with historical volatility in this time frame at 629.31%.
As of today, SEEL’s price is $0.1803 +12.95% or $0.0211 from its 5-day moving average. SEEL is currently trading -83.12% lower than its 20-day SMA and -77.76% lower than its 100-day SMA. However, the stock’s current price level is -87.48% below the SMA50 and -85.40% below the SMA200.
The stochastic %K and %D were 4.15% and 3.80%, respectively, and the average true range (ATR) was 0.0952. With the 14-day stochastic at 3.74% and the average true range at 0.1023, the RSI (14) stands at 21.95%. The stock has reached -0.0966 on the 9-day MACD Oscillator while the 14-day reading was at -0.3217.
Analyst Ratings
ROTH Capital upgraded Seelos Therapeutics Inc (NASDAQ: SEEL) to a a Buy rating in its most recent analyst report. Previously, the stock was rated as a Neutral. The consensus rating for Seelos Therapeutics Inc (SEEL) among analysts is Overweight. According to current brokerage recommendations, 0 brokerage firms advise that investors sell SEEL, while 2 suggest investors hold. There are 0 analysts who rate the stock as underweight. The stock is rated overweight by 0 analysts, while 2 others rate it as a “buy”.
What is SEEL’s price target for the next 12 months?
Analysts predict a range of price targets between $1.00 and $4.00, with a median target of $2.00. Taking a look at these predictions, the average price target given by analysts for Seelos Therapeutics Inc (SEEL) stock is $2.33.
